Transplantation in Special Populations

Transplantation in Special Populations - Tiny Titans, Big Hopes

• Pediatric transplantation: unique challenges in growth, neurodevelopment, adherence, psychosocial aspects.
• Anatomical: smaller vessels, organ size mismatch, technical modifications.
• Immunosuppression: weight/BSA-based dosing; ↑risk PTLD (EBV-driven), infections. Monitor long-term effects.
• Common indications:
  • Liver: Biliary atresia (most common).
  • Kidney: CAKUT (Congenital Anomalies of the Kidney and Urinary Tract).
  • Heart: Congenital heart defects.
• Growth & development: critical monitoring; nutritional support vital. Growth hormone considered.
• Living donor kidney transplant often preferred for better outcomes.

⭐ PTLD (Post-Transplant Lymphoproliferative Disorder), often EBV-related, is a significant concern in pediatric solid organ transplant, with incidence varying by organ and immunosuppression intensity.

Transplantation in Special Populations - Golden Years, New Leases

• Eligibility: Chronological age (e.g., >65 yrs) less critical than physiological age & comorbidities.
• Key Challenges:
  • ↑ Comorbidities (cardiac, diabetes, prior malignancy).
  • Immunosenescence: may ↓ rejection but ↑ infection/malignancy risk.
  • Polypharmacy & frailty assessment crucial.
• Evaluation: Comprehensive Geriatric Assessment (CGA) vital.
• Immunosuppression: Tailored regimens to balance efficacy against infection risk.
• Donor Considerations: Often utilize Expanded Criteria Donors (ECD).
• Outcomes: Good quality of life achievable; higher risk of infection, cardiovascular events.

⭐ Despite immunosenescence potentially reducing acute rejection, elderly transplant recipients face increased mortality from infections and cardiovascular events.

Transplantation in Special Populations - Viral Hurdles, Hopeful Horizons

• HIV+ Recipients:
  • Criteria: CD4 >200 cells/µL (some protocols >100), undetectable viral load (<50 copies/mL) for ≥6 months.
  • HAART essential; watch for drug interactions (CNIs, mTOR inhibitors).
• HIV+ Donors (e.g., HOPE Act principles):
  • Permitted for HIV+ recipients under specific research protocols and consent.
• Hepatitis B (HBV):
  • Recipients: Lifelong antiviral prophylaxis (e.g., Entecavir/Tenofovir) ± HBIG post-transplant.
  • HBcAb+ (core antibody positive) donors: Risk of de novo HBV in recipient; recipient requires prophylaxis.
• Hepatitis C (HCV):
  • Recipients: Direct-Acting Antivirals (DAAs) achieve Sustained Virologic Response (SVR) >95%. Treat pre or post-transplant. Untreated risks fibrosing cholestatic hepatitis.
  • HCV NAT+ donors: Increasingly used for HCV+ recipients; also for HCV- if DAAs are assured post-transplant.

⭐ HIV+ patients on stable HAART with an undetectable viral load and adequate CD4 count (typically >200 cells/µL) have post-transplant outcomes comparable to HIV-negative recipients.

Transplantation in Special Populations - Fertile Futures, Careful Crafting

• Pregnancy Post-Transplant:
  • High-risk; requires multidisciplinary care.
  • Optimal: 1-2 years post-transplant, stable graft, maintenance immunosuppression.
• Immunosuppression (Pregnancy):
  • AVOID: Mycophenolate (MMF/MPA) 📌 MMF = My Fetus Fails. Switch to Azathioprine (AZA) ≥6 weeks pre-conception.
  • USE: Tacrolimus (preferred CNI), low-dose Prednisolone.
  • CONTRAINDICATED: Sirolimus, Everolimus.
• Risks:
  • Maternal: Pre-eclampsia, gestational diabetes, infection, rejection.
  • Fetal: Prematurity, IUGR.
• Male Fertility: CNIs generally safe; Sirolimus/MMF may impair.
• Breastfeeding: Generally not advised; specialist consultation.

⭐ Mycophenolate (MMF/MPA) is highly teratogenic; switch to Azathioprine ≥6 weeks before conception.

High‑Yield Points - ⚡ Biggest Takeaways

• Pregnancy post-transplant is possible; avoid Mycophenolate Mofetil (MMF) and Sirolimus.
• Elderly recipients face ↑ infection and ↑ malignancy risks; cardiac fitness is crucial.
• Pediatric transplants risk growth issues and PTLD; non-adherence is a concern.
• HIV+ patients can be transplanted with undetectable viral load and good CD4 counts.
• HCV+ recipients can receive HCV+ organs; DAAs improve outcomes significantly.
• ABO-incompatible & highly sensitized patients: Transplant possible with desensitization protocols (e.g., IVIG, Rituximab).